文献速递骨质疏松与代谢性骨病

每月一次米诺膦酸与利塞膦酸在类风湿关节炎骨质疏松患者中的疗效:12个月随机头对头比较

Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
PubMed 文献 · Osteoporos Int · 2018-03-24

一项前瞻性随机开放标签头对头研究纳入83例类风湿关节炎患者,分别接受每月一次口服米诺膦酸50 mg(n=42)或利塞膦酸75 mg(n=41)治疗12个月。两组腰椎、全髋、股骨颈骨密度均显著升高且组间无显著差异,米诺膦酸组骨转换标志物降幅显著大于利塞膦酸组。

要点

  • 米诺膦酸与利塞膦酸治疗12个月后腰椎、全髋、股骨颈骨密度均显著升高,组间无显著差异。
  • 米诺膦酸组TRACP-5b、NTX、BAP降幅均显著大于利塞膦酸组。
  • 作者认为米诺膦酸是类风湿关节炎骨质疏松患者有前景的治疗选择。

核心结论

  • 在类风湿关节炎患者中,米诺膦酸增加骨密度的效果与利塞膦酸相同,抑制骨吸收的效果强于利塞膦酸,作者认为米诺膦酸是类风湿关节炎骨质疏松患者有前景的治疗选择。

研究设计与样本

  • 前瞻性、随机、开放标签、头对头比较研究,共83例类风湿关节炎患者随机分配至每月一次口服米诺膦酸50 mg组(n=42)或每月一次口服利塞膦酸75 mg组(n=41),疗程12个月,系列测量骨密度和骨转换标志物。

主要发现

  • 治疗12个月后米诺膦酸组腰椎、全髋、股骨颈骨密度分别升高3.8%、2.0%、2.2%(P < 0.05)。
  • 治疗12个月后利塞膦酸组腰椎、全髋、股骨颈骨密度分别升高3.6%、1.9%、1.9%(P < 0.05)。
  • 两组骨密度变化组间无显著差异。
  • 米诺膦酸组骨转换标志物从基线至12个月的百分比变化显著大于利塞膦酸组:TRACP-5b为-36.3% vs -19.3%(P < 0.05),NTX为-27.1% vs -17.3%(P < 0.05),BAP为-30.2% vs -19.4%(P < 0.05)。

临床怎么用

  • 原文未据此给出推荐,作者在结论中认为米诺膦酸是类风湿关节炎骨质疏松患者有前景的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: A head-to-head comparison of once-monthly oral bisphosphonates minodronate (MIN) and risedronate (RIS) in patients with rheumatoid arthritis (RA) demonstrated that MIN has the same effect as RIS on increase in bone mineral density (BMD) and a stronger effect on inhibition of bone resorption than RIS, suggesting that MIN is a promising treatment option for osteoporosis patients with RA. INTRODUCTION: To evaluate the effect of once-monthly oral MIN in patients with RA, a prospective, randomized, open-label, head-to-head comparison with once-monthly oral RIS was conducted. METHODS: A total of 83 patients with RA were randomly assigned to either once-monthly oral MIN 50 mg (n = 42) or once-monthly oral RIS 75 mg (n = 41). Serial BMD and bone turnover markers were measured and compared between the treatment groups. RESULTS: BMD (lumbar spine, total hip, femoral neck) increased significantly after 12 months of treatment with MIN (3.8, 2.0, and 2.2%, respectively, P < 0.05) and RIS (3.6, 1.9, and 1.9%, respectively, P < 0.05). There were no significant differences between the treatment groups. Percent changes of bone turnover markers from baseline to 12 months in the MIN group were significantly greater than those in the RIS group (TRACP-5b: - 36.3 vs - 19.3%, P < 0.05; NTX: - 27.1 vs - 17.3%, P < 0.05; BAP: -30.2 vs -19.4%, P < 0.05). CONCLUSIONS: The present study of RA patients demonstrated that MIN has the same effect as RIS on increase in BMD and a stronger effect on inhibition of bone resorption than RIS. The results suggest that MIN is a promising treatment option for osteoporosis patients with RA.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Kumagai K, Harigane K, Kusayama Y, et al. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison. Osteoporos Int. 2018. PMID: 29574518. doi:10.1007/s00198-018-4494-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。